This Report Provides In-Depth Analysis of the Neurostimulation Devices Market Report Prepared by P&S Intelligence, Segmented by Type (Implantable/Internal, External), Application (Pain Management, Failed Back Syndrome, Ischemia, Parkinson's Disease, Essential Tremor, Urinary and Fecal Incontinence, Epilepsy, Hearing Loss, Gastroparesis, Depression), End User (Hospitals, Specialty Clinics), and Geographical Outlook for the Period of 2019 to 2032
Explore the market potential with our data-driven report
Neurostimulation Devices Market Analysis
The global neurostimulation devices market size in 2024 was USD 7.2 billion, and it is expected to advance at a CAGR of 9.8% during 2025–2032, to reach USD 15.1 billion by 2032. Neurostimulation devices are used to treat neurological problems and chronic pain by giving tingling sensations to the injured nerve.
The neurostimulation technology uses microelectrodes to stimulate the nerves. The devices are the size of a stopwatch and powered by a battery. They are often surgically inserted into the brain, to generate paresthesia, a tingling sensation in the nerves, at predetermined time intervals. These electrical signals cause feelings in the injured neurons and aid in the treatment of chronic pain and neurological problems. In the event of chronic pain, these electrical signals aid in the blockage of pain messages from the neurons to the brain. These devices are typically employed in situations where pharmacological therapy is not effective.
The increasing prevalence of neurological illnesses and chronic pain and the growing geriatric population are, thus, driving the industry expansion. Furthermore, the increasing awareness of neurological illnesses and the rising investments in research and development for creative and revolutionary neurostimulation equipment are driving the market's growth. Moreover, there is an increasing demand for minimally invasive methods for the treatment of neurological illnesses.
Segmentation Analysis
End User Insights
Hospitals are the largest end user in the global neurostimulation devices market, holding 55% share in 2024. This is due to the well-established healthcare infrastructure, advantageous medical reimbursement policies for neurostimulation devices in industrialized nations, and the expensive nature of implantable devices. During the forecast period, the category is projected to be driven by an increase in the number of hospitals in emerging economies and the rise in the volume of neurostimulation device implantation procedures.
Specialty clinics are expected to witness the faster growth during the forecast period on account of the increasing adoption of advanced instruments at these places. Globally, there is a noticeable trend of patient treatment in outpatient settings, due to the overcrowding in hospital inpatient settings and high-cost nature of hospital care in industrialized countries. Moreover, several regional and national authorities are promoting patient treatment at home or in outpatient clinics.
In industrialized and developing countries, the growth in the count of specialty clinics for neurology, cardiology, and other fields of medicine is attracting a large patient pool. This, combined with the use of advanced tools, presence of a competent staff, and supportive reimbursement procedures for treatment in these settings, has resulted in an increase in the number of patients visiting specialized clinics for chronic pain, epilepsy, and other illnesses.
Thee end users have been analyzed:
Hospitals (Largest Category)
Specialty Clinics (Fastest-Growing Category)
Others
Application Insights
The market was dominated by the pain management category in 2024, and it will also witness the highest CAGR during the forecast period, of 10%. The main factors driving the expansion of this category are the increasing number of people with chronic pain and the rising usage of neuromodulation for pain management due to its high therapeutic efficacy. Regulatory authorities' clearance of the associated products is also accelerating the category’s expansion. Additionally, the category is set to advance as a result of the technical developments in the pain management industry and the various market strategies used by the major participants.
These applications have been analyzed:
Pain Management (Largest and Fastest-Growing Category)
Failed Back Syndrome
Ischemia
Parkinson's Disease
Essential Tremor
Urinary and Fecal Incontinence
Epilepsy
Hearing Loss
Gastroparesis
Others
Type Analysis
Implantable/internal is the larger category in the market, with 60% share in 2024, and it is also the fastest-growing category. This is due to the long-term action of these devices and the fact that they are a one-time investment. Implantable devices also remove the inconvenience of constantly carrying the devices along and adjusting them frequently. Additionally, since they are placed within the body, they are not visible, which enhances aesthetics for appearance-conscious individuals. This feature also makes them preferred among those still feeling the stigma of being diagnosed with mental disorders. Such patients often do not like other people knowing they are being treated for these conditions.
These types have been analyzed:
Implantable/Internal (Larger and Faster-Growing Category)
North America led the market in 2024 with 45% revenue due to the aging of the population and rise in the prevalence of neurological illnesses. The demand for neurostimulation devices is also rising as a result of the increasing preference for minimally invasive treatments and growing awareness of mental illnesses. Additionally, the rising R&D expenditure for the creation of innovative neurostimulation equipment is expected to result in the market growth.
It is expected that rapid economic development will further drive the neurostimulation device market growth in Europe, which is already expanding rapidly. Additionally, since it is easier to get a medical device approval in Europe than in the U.S., this region is witnessing a rapid increase in neurostimulation device sales. Additionally, the region's rising senior population is going to assist the industry expansion.
During the projection period, APAC is projected to develop at the highest CAGR, 10.5%. Due to the vast unmet medical needs and untapped development potential, North American and European manufacturers are swiftly shifting their manufacturing activities to this region. Furthermore, the APAC market advance is aided by the swiftly growing economies of China and India, along with the escalating costs of healthcare.
Moreover, the aging populations in several nations, including Brazil and Saudi Arabia, are causing the LATAM and MEA regions to expand quickly, respectively. Additionally, the rising prevalence of neurological illnesses and chronic pain are contributing to the expansion. During the projection period, the growth is set to be fueled by the indirect and direct entry of players in these regions.
Brazil (Largest and Fastest-Growing Country Market)
Mexico
Rest of LATAM
Middle East and Africa (MEA)
Saudi Arabia (Largest Country Market)
South Africa
U.A.E. (Fastest-Growing Country Market)
Rest of MEA
Neurostimulation Devices Market Share Analysis
The market is consolidated as the high capital and technical expertise required for research and development, device production, and clinical trials reduces the scope for new entrants.
Furthermore, new businesses attempting to enter the neurostimulation device industry need to clear a variety of regulatory criteria, thus reducing the threat from them to the established companies.
The industry is also characterized by a modest level of brand loyalty, as physicians suggest existing brands, which has a significant negative impact on the entry of new firms.
Furthermore, manufacturers are investing increasingly in R&D in order to develop sophisticated implantable neurostimulation devices.
These companies' strategic methods are focused on catering to more geographical areas and growing their revenue share.
Neurostimulation Devices Companies:
Aleva Neurotherapeutics SA
Medtronic plc
Boston Scientific Corporation
LivaNova PLC
NeuroPace Inc.
NeuroSigma Inc.
Synapse Biomedical Inc.
Neuronetics Inc.
Cochlear Ltd.
Soterix Medical Inc.
Abbott Laboratories
Integra LifeSciences Holdings Corporation
Neurostimulation Devices Market Developments
In January 2025, Nalu Medical received the MRI-Conditional label for its neurostimulation system from the FDA. This label means that the device, which had received the 510(k) clearance for spinal cord stimulation and peripheral nerve stimulation in 2020, is safe for usage inside an MRI.
In January 2025, Mainstay Medical Holdings plc announced positive results of a one-year RESTORE randomized clinical trial of its ReActiv8 neurostimulation system for intractable chronic low back pain. The device stimulates the nerves in the multifidus muscle to stabilize the lumbar region of the spine, thus reducing back pain.
In November 2024, Tivic Health announced that it has completed the enrolment of candidates for an optimization study on its non-invasive vagus nerve stimulation device, for which a patent application has already been submitted. Being conducted by the Feinstein Institute of Bioelectronic Medicine, the study aims to highlight how the device can be best used to enhance the functioning of the autonomic nervous system.
In September 2024, Zynex Inc. received the FDA’s 510(k) approval for its TensWave device. Available only via prescription, this transcutaneous electrical nerve stimulation is designed to treat acute and chronic pain without painkillers.
Frequently Asked Questions About This Report
What is the neurostimulation devices market competitive scenario?+
The market for neurostimulation devices is consolidated.
What will be the size of the neurostimulation devices industry in 2032?+
The neurostimulation devices industry size in 2032 will be USD 15.1 billion.
Which type is more popular in the neurostimulation devices market?+
The implantable/internal type leads the market for neurostimulation devices.
Which is the key opportunity in the neurostimulation devices industry?+
The rising awareness of mental disorders offers opportunities in the neurostimulation devices industry.
Which region dominates the neurostimulation devices market?+
The largest share in the market for neurostimulation devices is held by North America.
Want a report tailored exactly to your business need?
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
